4DMT to Participate in Upcoming Investor Conferences
05 March 2024 - 12:00AM
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company),
a leading clinical-stage genetic medicines company focused on
unlocking the full potential of genetic medicines to treat large
market diseases, today announced that management will
participate in fireside chats at upcoming investor conferences in
March. Members of the management team will also be available for
one-on-one meetings.
Leerink Partners Global Biopharma Conference
2024
Presentation Date: |
Tuesday, March 12, 2024 |
Presentation Time: |
11:20 a.m. ET |
Webcast Link: |
Webcast |
Barclays 26th Annual Global Healthcare
Conference
Presentation Date: |
Wednesday, March 13, 2024 |
Presentation Time: |
8:30 a.m. ET |
Webcast Link: |
Webcast |
Archived copies of the webcasts will be available for up to one
year by visiting the “Investors” section of the 4DMT website
at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading clinical-stage genetic medicines company
focused on unlocking the full potential of genetic medicines to
treat large market diseases in ophthalmology and pulmonology.
4DMT’s proprietary invention platform, Therapeutic Vector
Evolution, combines the power of the Nobel Prize-winning
technology, directed evolution, with approximately one billion
synthetic AAV capsid-derived sequences to invent customized and
evolved vectors for use in our wholly owned and partnered product
candidates. Our product design, development, and manufacturing
engine helps us efficiently create and advance our diverse product
pipeline with the goal of revolutionizing medicine with potential
curative therapies for millions of patients. Currently, 4DMT is
advancing five clinical-stage and two preclinical product
candidates, each tailored to address rare and large market diseases
in ophthalmology, pulmonology, and cardiology. In addition, 4DMT is
also advancing programs in CNS through a gene editing partnership.
4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™,
and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical
development and have not yet been approved for marketing by the FDA
or any other regulatory authority. No representation is made as to
the safety or effectiveness of our product candidates for the
therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us
on LinkedIn.
Contacts:
Media:
Katherine SmithInizio Evoke
CommsKatherine.Smith@inizioevoke.com
Investors:
Julian PeiHead of Investor Relations and Corporate
CommunicationsInvestor.Relations@4DMT.com
4D Molecular Therapeutics (NASDAQ:FDMT)
Historical Stock Chart
From Apr 2024 to May 2024
4D Molecular Therapeutics (NASDAQ:FDMT)
Historical Stock Chart
From May 2023 to May 2024